robatumumab + ifosfamide + etoposide

Robatumumab + ifosfamide + etoposide is an experimental combination regimen consisting of: - **Robatumumab**: a fully human monoclonal antibody (IgG1/kappa isotype) that selectively targets and inhibits insulin-like growth factor 1 receptor (IGF-1R), blocking IGF ligand binding, receptor autophosphorylation, and downstream oncogenic signaling events. Robatumumab additionally induces IGF-1R degradation and mediates antibody-dependent cellular cytotoxicity against tumor cells. It was developed primarily for treatment of sarcomas, including Ewing sarcoma and osteosarcoma[1][3][5][7][9]. - **Ifosfamide**: an alkylating antineoplastic small molecule used widely as chemotherapy, particularly in lymphomas and sarcomas. It covalently modifies DNA by forming cross-links, leading to cell death, particularly in rapidly dividing cells[2][4][6]. - **Etoposide**: a topoisomerase II inhibitor that induces DNA strand breaks and apoptosis, also primarily used as chemotherapy in lymphomas, germ cell tumors, and sarcomas. This combination is investigational and may be used for advanced, refractory, or relapsed soft tissue or bone sarcomas, though clinical trials are limited and the specific combination is not a standard regimen in clinical protocols. Each agent in the combination acts via a distinct, complementary mechanism to exert antineoplastic activity[1][3][7][9].